Core 2: Biospecimen, Metabolomics, and Pathology Core
核心 2:生物样本、代谢组学和病理学核心
基本信息
- 批准号:10711640
- 负责人:
- 金额:$ 13.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-23 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AwardBiostatistics CoreBloodCancer CenterCancer ModelCancer PatientCatalogsCellsCharacteristicsClinicalClinical DataCollaborationsCollectionCommunitiesConsentCorrelative StudyCredentialingDataDatabasesDevelopmentDiagnosisDiseaseEligibility DeterminationEndometrial CarcinomaEnsureEquipment and supply inventoriesEquityEvaluationExperimental DesignsFreezingFutureGoalsGrantInfrastructureInstitutionInstitutional Review BoardsIsotopesLeadershipLinkLiquid substanceManuscriptsMetabolicMethodsNew MexicoNewly DiagnosedNucleic AcidsOklahomaOrganoidsOutcomePathologyPatientsPeer ReviewPlasmaPreparationProcessPrognostic FactorProtocols documentationPublicationsQualifyingRecurrenceResearchResearch DesignResearch PersonnelResearch Project GrantsResourcesRouteSamplingSerumServicesSpecimenStandardizationStructureTimeTissuesTranslational ResearchUniversitiesValidationWashingtonWorkanticancer researchbiobankcareerclinical databasedata interoperabilitydata sharingexperiencegenome sequencingmetabolomicsmodel developmentoperationpatient derived xenograft modelpreservationpreventprogramsprospectivesample collectionsecondary analysissuccesstoolwhole genome
项目摘要
PROJECT SUMMARY/ABSTRACT
The goal of the Biospecimen, Metabolomics, and Pathology Core (BMP Core) is to create a federated, multi-
institutional resource to provide high-quality, clinically annotated biospecimens, metabolomic analyses, and
expert pathology review to all research projects in this SPORE application as well as future SPORE-sponsored
DRP and CEP projects, while serving as an unparalleled biospecimen resource to the broader endometrial
cancer research community. The Core will provide specific tissue and biosample-related services for each
SPORE project. In addition, the BMP Core will prospectively build a biospecimen resource bank at WUSTL,
OUHSC, and UNM by identifying cases of new and recurrent endometrial cancer at the participating institutions
and facilitating the consent and procurement process. Tissue and fluid biospecimens from these patients will
be collected, processed, and stored by leveraging the extensive infrastructure of existing biorepositories at the
participating institutions. Clinical data will be collected prospectively by integrating with and extending existing
clinical databases. Interactions with the Biostatistics Core will ensure interoperability of data tables maintained
at each institution. The BMP Core will provide access to the world-class Center for Metabolomics and Isotope
Tracing at WUSTL. Validated methods for sample processing and preservation, focused on optimizing
metabolic analyses, will be provided to increase the scientific utility of all biospecimens collected. A
transparent and equitable mechanism to publicize existing biospecimen resources and evaluate any request
for their use will be implemented. As such, the BMP Core will supplement existing cancer center resources
with focused expertise and effort to comprehensively collect, annotate, quality review, and distribute
biospecimens specifically for translational endometrial cancer research.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ian S. Hagemann其他文献
Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids
Neratinib 与曲妥珠单抗抗体药物偶联物或长春瑞滨协同治疗 HER2 突变乳腺癌患者的异种移植物和类器官
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Shunqiang Li;Tina M Primeau;Maureen K. Highkin;S. L. Pratt;Ashley R. Tipton;Nagalaxmi Vemalapally;J. Monsey;Yu Tao;Jingqin Luo;Ian S. Hagemann;Chieh;L. Eli;Cynthia X Ma;R. Bose - 通讯作者:
R. Bose
Pathologic findings in fallopian tubes of women with chronic pelvic pain after Essure placement
- DOI:
10.1016/j.contraception.2020.04.010 - 发表时间:
2020-08-01 - 期刊:
- 影响因子:
- 作者:
Alexandra Rubin;Jie-Fu Chen;Ashley Veade;Ian S. Hagemann - 通讯作者:
Ian S. Hagemann
Controversies in Gynecologic Cancer Staging: An AJCC Cancer Staging Manual, Eighth Edition Perspective
妇科癌症分期的争议:AJCC 癌症分期手册,第八版观点
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Ian S. Hagemann;Lisa L. Cole;Jonathan A. Cosin;Donna M. Gress;David G. Mutch;A. Olawaiye - 通讯作者:
A. Olawaiye
E2f8 Is a Nonreceptor Activator of Heterotrimeric G Proteins Recommended Citation Journal of Molecular Signaling Open Access E2f8 Is a Nonreceptor Activator of Heterotrimeric G Proteins
E2f8 是异三聚 G 蛋白的非受体激活剂 推荐引文 分子信号转导开放获取杂志 E2f8 是异三聚 G 蛋白的非受体激活剂
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
Ian S. Hagemann;Kirk D Narzinski;Thomas J. Baranski;Kirk;J. Baranski - 通讯作者:
J. Baranski
Ian S. Hagemann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Administrative, data management and biostatistics core
行政、数据管理和生物统计核心
- 批准号:
10642593 - 财政年份:2023
- 资助金额:
$ 13.04万 - 项目类别:
HABS-HD - Core F - Biostatistics Core
HABS-HD - 核心 F - 生物统计学核心
- 批准号:
10493850 - 财政年份:2022
- 资助金额:
$ 13.04万 - 项目类别:
HABS-HD - Core F - Biostatistics Core
HABS-HD - 核心 F - 生物统计学核心
- 批准号:
10708883 - 财政年份:2022
- 资助金额:
$ 13.04万 - 项目类别:














{{item.name}}会员




